TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23555876

Group type: EXPERIMENTAL
Intervention: Active vocalization with pitch-shifted voice (100 cents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active vocalization with pure tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active vocalization with white noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive listening
Number of subjects: 0
Study: 21873356

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 124

Group type: COMPARATOR
Intervention: Absorbable hemostat
Number of subjects: 124
Study: 19752838

Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 337

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 337
Study: 16423942

Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg of iohexol over 35 sec (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.7 mL/kg of iohexol over 35 sec (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5 mL/kg of iohexol over 35 sec (Group C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.7 mL/kg of iohexol over 25 sec (Group D)
Number of subjects: 20
Study: 15579515

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study: 11434896

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 0
Study: 9737753

Group type: EXPERIMENTAL
Intervention: Fluid formulation with 157 Na (270 mOsm x kg(-1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluid formulation with Performance (19.6 mEq x L(-1) Na, 380 mOsm)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluid formulations with 19.6 Na or 19.6 Na + glucose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water during exercise
Number of subjects: 9
Study: 8070505

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg controlled-release (CR) tablet bd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg controlled-release (CR) tablet bd
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diltiazem 60 mg immediate-release (IR) tablet tid
Number of subjects: 12
Study: 2660558

Group type: COMPARATOR
Intervention: Cimetidine 200 mg three times a day and 400 mg at night
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day orally for four weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 140
Study: 30787094

Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) with weight appropriate transnasal flow rates and 100% oxygen
Number of subjects: 960

Group type: COMPARATOR
Intervention: Control (no transnasal oxygen insufflation)
Number of subjects: 960
Study: 29888547

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 26965717

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 32
Study: 25119686

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator microspirometry test (FEV1/FEV6 <0.73)
Number of subjects: 104
Study: 22361399

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg intravenously)
Number of subjects: 16
Study: 19927040

Group type: EXPERIMENTAL
Intervention: MenC-CRM booster
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: MenC-TT booster
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: MenC vaccine booster
Number of subjects: 389

Group type: COMPARATOR
Intervention: MenC-CRM primed
Number of subjects: 389

Group type: COMPARATOR
Intervention: MenC-TT primed
Number of subjects: 389
Study: 17650521

Group type: EXPERIMENTAL
Intervention: Etoricoxib, Febuxostat, Pegylated-uricase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15616045

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution (IH) performed with 500 mL; identical volume of hydroxyethyl starch administered.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (group CTRL) underwent the same sequences of one-lung ventilation (OLV) without IH.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Normal lung function (group NL) underwent IH.
Number of subjects: 47
Study: 11788629

Group type: EXPERIMENTAL
Intervention: Low dose GH (0.025 mg/kg per day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Medium dose GH (0.05 mg/kg per day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High dose GH (0.1 mg/kg per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 10430551

Group type: EXPERIMENTAL
Intervention: ET (fentanyl) with 200 microA direct current applied for 30 min at hourly intervals
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ET (fentanyl) with 200 microA direct current applied for 30 min at 4-hourly intervals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous fentanyl 75 microg infused over 30 min every 4 h
Number of subjects: 9
Study: 7560622

Group type: EXPERIMENTAL
Intervention: 12,500 IU of unfractionated heparin given subcutaneously twice daily for 4 months
Number of subjects: 339

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 339
Study: 2245983

Group type: EXPERIMENTAL
Intervention: 500 mg clotrimazole vaginal tablet (n = 33)
Number of subjects: 62
Study: 7430504

Group type: EXPERIMENTAL
Intervention: 50 mg prednisone (single dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three 50 mg prednisone doses given at 6-hr intervals
Number of subjects: 15
Study: 6391933

Group type: EXPERIMENTAL
Intervention: 1200 mg fenclofenac per day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gold in standard doses
Number of subjects: 35
Study: 30912735

Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g, 72% cocoa)
Number of subjects: 16
Study: 28304188

Group type: EXPERIMENTAL
Intervention: Unilateral left thalamic Vim stimulation (DBS on)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Low-voltage Vim stimulation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Multitarget Vim + Voa stimulation
Number of subjects: 1

Group type: COMPARATOR
Intervention: No stimulation (DBS off)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Low-voltage Voa stimulation
Number of subjects: 1
Study: 27068478

Group type: EXPERIMENTAL
Intervention: Intravenously administered iron saccharate (200 mg, two applications)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Orally administered iron polymaltose complex (100 mg, twice a day for 8 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intravenously administered iron saccharate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Orally administered iron polymaltose complex
Number of subjects: 56
Study: 24846620

Group type: EXPERIMENTAL
Intervention: TelePain intervention (report of symptoms and receipt of a pain graph) weekly for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TelePain sessions for health care providers (didactic presentation on pain management and patient case discussions)
Number of subjects: 0
Study: 22420597

Group type: EXPERIMENTAL
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: quetiapine (25-300 mg, flexibly dosed)
Number of subjects: 25
Study: 19465506

Group type: EXPERIMENTAL
Intervention: Visuospatial hemineglect
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control for severity of paresis
Number of subjects: 53
Study: 18408401

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (clinical breast examination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for cervix cancer (visual inspection of the cervix after application of 4% acetic acid)
Number of subjects: 0
Study: 15939920

Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/qm(2) on day 1 and methotrexate 40 mg/qm(2) on days 8 and 15 of a 21-day cycle (CM)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Methotrexate 30 mg/qm(2) on days 1, 15, and 22, vinblastine 3 mg/qm(2) on days 2, 15, and 22, epirubicin 45 mg/qm(2) on day 2, and cisplatin 70 mg/qm(2) on day 2 of a 28-day cycle (M-VEC)
Number of subjects: 327
Study: 12424822

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics (AN)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Classical neuroleptics (CN)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duration of neuroleptic treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 75
Study: 10325444

Group type: EXPERIMENTAL
Intervention: Silymarin (420 mg/day) + Tacrine (40 mg/day for 6 weeks, then increased to 80 mg/day for 6 weeks)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Tacrine + Placebo
Number of subjects: 222
Study: 7544524

Group type: EXPERIMENTAL
Intervention: Consolidation therapy
Number of subjects: 1
Study: 2027114

Group type: EXPERIMENTAL
Intervention: Orgotein (4 or 8 mg)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 419
Study: 6909683

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 31447483

Group type: EXPERIMENTAL
Intervention: Low-pass genome sequencing (GS)
Number of subjects: 1023
Study: 29363535

Group type: EXPERIMENTAL
Intervention: Endocuff Vision (EAC)
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 1772
Study: 27825551

Group type: EXPERIMENTAL
Intervention: 30s recovery
Number of subjects: 10

Group type: COMPARATOR
Intervention: 180s recovery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both recovery times
Number of subjects: 10
Study: 25892348

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 82
Study: 23650901

Group type: EXPERIMENTAL
Intervention: Patch pump (PP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pump (CP)
Number of subjects: 20
Study: 21896198

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.12% saline (placebo)
Number of subjects: 12
Study: 19781874

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Related agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cautious approach based on scientific data
Number of subjects: 0
Study: 18159013

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional empirical therapy (Control)
Number of subjects: 273
Study: 15321022

Group type: EXPERIMENTAL
Intervention: Grid laser photocoagulation and 0.5 mL of 40 mg/mL posterior subtenon triamcinolone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Grid laser photocoagulation only
Number of subjects: 31
Study: 12646340

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 615

Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 615

Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 615

Group type: COMPARATOR
Intervention: pravastatin 20 mg
Number of subjects: 615
Study: 10068342

Group type: EXPERIMENTAL
Intervention: Tissue PSA (T-PSA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Serum PSA (S-PSA)
Number of subjects: 104
Study: 7556733

Group type: EXPERIMENTAL
Intervention: Novel conjunctival incision technique
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 13
Study: 2330116

Group type: EXPERIMENTAL
Intervention: Combination of levodopa and carbidopa
Number of subjects: 6

Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 6
Study: 7408140

Group type: EXPERIMENTAL
Intervention: Dipyridamole (Persantine) and aspirin
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2026
Study: 31912785

Group type: EXPERIMENTAL
Intervention: Electronic symptom monitoring intervention
Number of subjects: 766

Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 766
Study: 30232855

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study: 26849264

Group type: EXPERIMENTAL
Intervention: Solvent exposure
Number of subjects: 481

Group type: COMPARATOR
Intervention: Endotoxin and metals exposure
Number of subjects: 481
Study: 24275067

Group type: EXPERIMENTAL
Intervention: Patients' contribution to the alliance
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Therapists' contribution to the alliance
Number of subjects: 133

Group type: COMPARATOR
Intervention: Therapist effects
Number of subjects: 133
Study: 22434051

Group type: EXPERIMENTAL
Intervention: High GI high carbohydrate meal (HGI-HC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low GI high carbohydrate meal (LGI-HC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low GI moderately high in protein and fat meal (LGI-MPF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: All meals (HGI-HC, LGI-HC, LGI-MPF)
Number of subjects: 32
Study: 20339615

Group type: EXPERIMENTAL
Intervention: DTPw-HepB-Hib fully liquid vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPw and Hib vaccines administered separately
Number of subjects: 0
Study: 18311434

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15811188

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 42
Study: 12459614

Group type: EXPERIMENTAL
Intervention: Cassava flour ('seca')
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cassava flour ('d'água')
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sweet made from cupuaçú (positive control)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fish (tambaqui) (negative control)
Number of subjects: 19
Study: 11039639

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity exercise group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 0
Study: 8970607

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 20
Study: 1894496

Group type: EXPERIMENTAL
Intervention: Active PEMF therapy (pulsed electromagnetic fields)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inactive PEMF therapy (control)
Number of subjects: 19
Study: 6361794

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Diflunisal 750 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 30569790

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg‐1 of body mass)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (3 mg·kg‐1 of body mass of dextrose)
Number of subjects: 21
Study: 30176391

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation for 16 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 26275787

Group type: EXPERIMENTAL
Intervention: Resistance exercise (leg press, chest press, knee flexion, lat pulldown, knee extension at 65% one-repetition maximum for three sets of 10 repetitions)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 25147092

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 109

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 109
Study: 22465901

Group type: EXPERIMENTAL
Intervention: Wellmune (250 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (identical rice flour-based)
Number of subjects: 100
Study: 20044683

Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg)
Number of subjects: 58
Study: 17963483

Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard information website (control)
Number of subjects: 0
Study: 15905884

Group type: EXPERIMENTAL
Intervention: Guolin qigong
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 88

Group type: COMPARATOR
Intervention: Guolin qigong and Conventional exercise
Number of subjects: 88
Study: 11835040

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Number of subjects: 89
Study: 9895080

Group type: EXPERIMENTAL
Intervention: remifentanil 0.04 microg x kg(‐1) x min(‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: remifentanil 0.07 microg x kg(‐1) x min(‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: remifentanil 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: remifentanil (all doses)
Number of subjects: 160
Study: 7735336

Group type: EXPERIMENTAL
Intervention: GHRH + Arginine (0.5 g/kg infused over 30 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GHRH + Pyridostigmine (120 mg orally at -60 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GHRH alone (1 microgram/kg i.v. at 0 min)
Number of subjects: 30
Study: 8182272

Group type: EXPERIMENTAL
Intervention: 25 units of viral protein antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12.5 units of viral protein antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6.25 units of viral protein antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: All doses
Number of subjects: 0
Study: 3002577

Group type: EXPERIMENTAL
Intervention: Lumpectomy (L)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lumpectomy with postoperative irradiation (LX)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lumpectomy without postoperative irradiation (LO)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Total mastectomy (TM)
Number of subjects: 78
Study: 31597496

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study: 29150790

Group type: EXPERIMENTAL
Intervention: Yishen Qufeng Shengshi Recipe (YQSR), 200 mL, twice per day, orally for 6 months
Number of subjects: 145

Group type: COMPARATOR
Intervention: Losartan, 50 mg/d orally for 6 months
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Yishen Qufeng Shengshi Recipe (YQSR)
Number of subjects: 145
Study: 26806592

Group type: EXPERIMENTAL
Intervention: Conventional canola oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High oleic canola oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High oleic canola oil enriched with DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flax/safflower oil blend
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn/safflower oil blend
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNP rs324420 carriers
Number of subjects: 0
Study: 26506579

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment for Adolescent Bulimia Nervosa (FBT-BN)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy adapted for adolescents (CBT-A)
Number of subjects: 130
Study: 23372142

Group type: EXPERIMENTAL
Intervention: Calcium channel blockade (CCB) - 60 mg oral nimodipine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21912808

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study: 19233107

Group type: EXPERIMENTAL
Intervention: Network-led care for severe heart failure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management for severe heart failure (control group)
Number of subjects: 0
Study: 16646722

Group type: EXPERIMENTAL
Intervention: Verum acupuncture based on Traditional Chinese Medicine (TCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 14656278

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (carboplatin or new drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum combination-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent new drug
Number of subjects: 0
Study: 11025952

Group type: EXPERIMENTAL
Intervention: Amrinone infusion (17 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Milrinone infusion (15 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Olprinone infusion (14 patients)
Number of subjects: 46
Study: 9710028

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 8311271

Group type: EXPERIMENTAL
Intervention: Lumbar epidural sufentanil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Thoracic epidural sufentanil
Number of subjects: 22
Study: 3396573

Group type: EXPERIMENTAL
Intervention: 12% glucose/electrolyte beverage (HC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6% glucose/electrolyte beverage (MC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: flavored water placebo (P)
Number of subjects: 15
Study: 30525053

Group type: EXPERIMENTAL
Intervention: Corneal Subbasal Nerve Plexus (SNP) changes in severe DNOAP patients using in vivo Corneal Confocal Microscopy (CCM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 26
Study: 26603531

Group type: EXPERIMENTAL
Intervention: Plasma prekallikrein (PK) levels in the highest 10th percentile
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Plasma prekallikrein (PK) levels
Number of subjects: 636